Eli Lilly’s EBGLYSS Yields 94% EASI-75, 75% EASI-90 Rates Over Four Years
EBGLYSS achieved 94% EASI-75 and 75% EASI-90 responses with 78% of atopic dermatitis patients reporting Pruritus NRS ≤4 after up to four years of monthly maintenance in the ADlong Phase 3b extension. Eighty percent of patients maintained these results without topical corticosteroids.
1. Four-Year Efficacy Data
In the ADlong Phase 3b extension, EBGLYSS delivered durable control in moderate-to-severe atopic dermatitis, with 94% of patients achieving EASI-75, 75% reaching EASI-90 and 78% reporting Pruritus NRS scores of ≤4 under once-monthly maintenance dosing.
2. Safety and Tolerability
Over the first year, adverse events were predominantly mild or moderate, with treatment-related conjunctivitis in 6.9% of patients and injection-site reactions in 0.6%, and no new safety signals observed during extended use.
3. Clinical and Commercial Implications
With 80% of patients maintaining efficacy without topical corticosteroids and 77% on monotherapy, EBGLYSS’s long-term data could enhance its positioning in the atopic dermatitis market and support broader payer coverage and adoption.